• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    11/29/22 4:32:56 PM ET
    $AGTC
    $AKAN
    $ALZN
    $NKTR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AGTC alert in real time by email

    Gainers

    • Akanda (NASDAQ:AKAN) shares increased by 33.5% to $0.28 during Tuesday's after-market session. Trading volume for this security closed at 442.1K, accounting for 67.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.6 million.
    • Coeptis Therapeutics (NASDAQ:COEP) stock rose 15.6% to $2.0. The market value of their outstanding shares is at $10.2 million.
    • Nektar Therapeutics (NASDAQ:NKTR) stock moved upwards by 12.71% to $3.28. The company's market cap stands at $616.4 million.
    • Viridian Therapeutics (NASDAQ:VRDN) shares rose 9.26% to $25.0. The market value of their outstanding shares is at $1.0 billion.
    • VistaGen Therapeutics (NASDAQ:VTGN) shares increased by 7.97% to $0.15. Trading volume for this security closed at 295.7K, accounting for 5.0% of its average full-day volume over the last 100 days. The company's market cap stands at $30.8 million.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 7.62% to $0.69. The company's market cap stands at $1.8 million.

    Losers

    • X4 Pharmaceuticals (NASDAQ:XFOR) shares fell 10.8% to $1.65 during Tuesday's after-market session. This security traded at a volume of 954.9K shares come close, making up 115.3% of its average volume over the last 100 days. The company's market cap stands at $114.2 million.
    • Alzamend Neuro (NASDAQ:ALZN) shares decreased by 7.63% to $1.09. The company's market cap stands at $105.0 million.
    • Ontrak (NASDAQ:OTRK) stock decreased by 5.71% to $0.38. The company's market cap stands at $10.2 million.
    • Redhill Biopharma (NASDAQ:RDHL) shares declined by 5.49% to $0.33. Today's trading volume for this security ended up closing at 388.1K shares, which is 13.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $21.2 million. The company's, Q3 earnings came out today.
    • Otonomy (NASDAQ:OTIC) stock fell 5.38% to $0.22. Otonomy's trading volume hit 21.0 million shares by close, accounting for 700.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $12.3 million.
    • Applied Genetic Techs (NASDAQ:AGTC) shares declined by 4.81% to $0.37. The market value of their outstanding shares is at $25.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGTC
    $AKAN
    $ALZN
    $NKTR

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    3/24/2026$70.00Neutral
    Wedbush
    Nektar Therapeutics
    $NKTR
    3/17/2026Buy
    TD Cowen
    X4 Pharmaceuticals Inc.
    $XFOR
    3/9/2026$12.00Buy
    Guggenheim
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    More analyst ratings

    $AGTC
    $AKAN
    $ALZN
    $NKTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Executive Chairman Craig Adam R bought $249,997 worth of shares (86,206 units at $2.90), increasing direct ownership by 30% to 376,087 units (SEC Form 4)

    4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

    10/27/25 6:40:40 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Fairmount Funds Management Llc bought $9,999,990 worth of shares (454,545 units at $22.00) (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    10/27/25 4:30:38 PM ET
    $VRDN
    Medical Specialities
    Health Care

    $AGTC
    $AKAN
    $ALZN
    $NKTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGTC
    $AKAN
    $ALZN
    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Tsimchi Ofer

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/19/26 7:35:14 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Scruggs Rick D

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/18/26 1:16:07 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Reed Kenneth

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/18/26 1:14:09 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGTC
    $AKAN
    $ALZN
    $NKTR
    SEC Filings

    View All

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    4/2/26 5:25:02 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    4/2/26 4:16:35 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    3/31/26 12:55:51 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AGTC
    $AKAN
    $ALZN
    $NKTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 32,000 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into

    4/1/26 4:30:00 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

    - REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 - - Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24 - - Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment - - REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027 - - Viridian ended Q4 2025 with $875 million in cash; the company anticipates exist

    3/30/26 7:01:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

    Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patientsRezpegaldesleukin proof-of-concept data in alopecia areata patients presented as a late-breaking research oral presentationSAN FRANCISCO, March 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver, CO. At AAD 2026, data from the global Phase 2b REZOLVE-AD study in 393 patients with moder

    3/28/26 12:36:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGTC
    $AKAN
    $ALZN
    $NKTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Nektar Therapeutics with a new price target

    Wedbush initiated coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $70.00

    3/24/26 8:19:49 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Nektar Therapeutics

    TD Cowen initiated coverage of Nektar Therapeutics with a rating of Buy

    3/17/26 7:57:51 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on X4 Pharmaceuticals with a new price target

    Guggenheim initiated coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    3/9/26 9:13:19 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGTC
    $AKAN
    $ALZN
    $NKTR
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Vistagen Appoints Paul Edick to its Board of Directors

    Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,

    10/29/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $AGTC
    $AKAN
    $ALZN
    $NKTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:53:44 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:52:18 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 5:05:41 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGTC
    $AKAN
    $ALZN
    $NKTR
    Financials

    Live finance-specific insights

    View All

    Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

    - REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 - - Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24 - - Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment - - REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027 - - Viridian ended Q4 2025 with $875 million in cash; the company anticipates exist

    3/30/26 7:01:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care